The purpose of this Framework Operation is to provide direct Standard Venture Debt (SVD) to innovative companies developing technologies for applications in life sciences and health, including, for example, development, validation, market entry and manufacturing of vaccines and other preventive measures, therapeutics and diagnostics, as well as initiatives aimed at strengthening the research, testing, development and implementation of innovative solutions for the transformation of health and care systems. It addresses unmet medical and public needs, suitable to strengthen the EU's position in Health, as defined in lnvestEU.
|InvestEU operation amount||EUR 750 million|
|Sector||Section C: Manufacturing Section M: Professional, Scientific and Technical Activities Section Q: Human Health and Social Work Activities|
|Policy window||Research, innovation and digitisation (RIDW)|
|Approval by the Investment Committee||08 July 2022|
Links and documents
Programme loans (“PL”) represent envelopes under which the Implementing Partner then can add sub-projects. The PL is published when the first sub-project is signed (see link above). The field “Project locations” references the possible geographical location of sub-projects that can be signed under the PL. It does not mean that for each of the Member State listed a signed sub-project exists.
Disclaimer: The Commission gives no warranty and makes no representation, whether expressed or implied, that the information is error free. The information is provided without any guarantees, conditions, or warranties as to its accuracy. This portal is made available for information purposes only.
- Eligible areas
- Research, development and innovationSMEs and small mid-capsSocial investments
- Implementing partner
- Policy window
- Research, innovation and digitisation (RIDW)